BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data

• BioVie completed enrollment in its Phase 2 ADDRESS-LC trial of bezisterim for neurological symptoms linked to long COVID.
• Topline results have not been presented; data are targeted for release in late summer 2026.
• The study is designed to evaluate whether bezisterim can ease disabling neurocognitive and neuropsychiatric symptoms; no FDA-approved treatments exist.
• Trial funding comes from a grant from the U.S. Department of War, reducing near-term development spending for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260800PRIMZONEFULLFEED9723242) on May 26, 2026, and is solely responsible for the information contained therein.